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Guillain-Barr´ esyndrome(GBS)isanacuteorsubacuteperipheralpolyneuropathycharacterizedbysymmetricalmuscleweakness.
Its occurrence has been reported during acute HIV seroconversion since 1985. Among HIV-infected subjects, GBS has generally a
favourable outcome. We report a case of GBS with fatal outcome during HIV seroconversion.
1.Introduction
Guillain-Barr´ e syndrome (GBS) is an acute or subacute
peripheral polyneuropathy characterized by symmetrical
muscle weakness occurring in the absence of identiﬁable
causes of genetic, metabolic, or toxic origin. The charac-
teristic presentation of the syndrome involves symmetrical
paresis or paresthesia of an ascending nature, with reduction
or loss of deep reﬂexes and variable autonomic dysfunction.
Signs and symptoms observed in the course of GBS are
extremely variable. The observed dysfunctions can be motor,
sensory, or autonomic (Table 1)[ 1, 2]. Diagnostic approach
to GBS is based on clinical, laboratory, and electrophysio-
logical criteria (Table 1). Progressive motor weakness and
areﬂexiaareprimerequirementsfordiagnosis.Cerebrospinal
ﬂuid analysis is the only laboratory criterion. Guillain-Barr´ e
syndrome onset is associated with a history of infection,
mainly of viral origin. Many patients with GBS describe a
febrile illness followed by an ascending paralysis occurring
days to weeks later. Actually, symptoms are preceded by an
antecedent event in about two thirds of cases. Respiratory
infections are the commonest, reported in about 40% of
caseswithinonemonthbeforetheonsetofthedisease.About
20% of patients experience gastroenteritis as the antecedent
cause[1].Since1985,severalcasesofthediseaseamongHIV-
infected patients have been reported, with GBS occurring
concomitantly with HIV seroconversion or during the initial
phasesofinfection[3–10].Infact,HIVinfectionisoneofthe
most common causes of this syndrome in African countries,
India, and other developing countries. In addition, cases
of GBS associated with the immunological reconstitution
induced by the use of antiretroviral therapy have also been
reported [11, 12]. GBS has frequently a favourable outcome
in HIV-infected subjects [3–12].
To our knowledge, we report the ﬁrst case of GBS with
fatal outcome during HIV seroconversion.
2. Case Presentation
A 56-year-old man who had already been observed at our
department for acute B (1988) and A (2000) hepatitis was
evaluatedatourOutpatientUnit(OPD).Hismedicalhistory
included viral encephalitis at age 6, chronic inﬂammatory
bowel disease (treated with mesalazine), and past surgery
for discal hernia. Homosexual intercourse with risk for
HIV transmission was reported. He had tested HIV-negative
about six-months before.
When presenting at our OPD, the patient reported the
occurrence of fever (up to 38◦C) and diﬀused maculo-
papularrashaboutonemonthearlier.Atthattime, headache
andintensepulsatorypainatshouldershadalsobeenpresent
for a few days. Blood tests showing evidence of probable
acute viral infection had also been performed. During the2 Case Reports in Infectious Diseases
Table 1: Characteristics clinical features of Guillain-Barr´ e syndrome and recommended diagnostic investigations.
Clinical features of
Guillain-Barr´ e syndrome Recommended diagnostic investigations
Motor dysfunctions Symmetrical limb weakness: proximal, distal or glob-
al; typically distal to proximal and rapidly ascending Cerebrospinal ﬂuid examination
Muscle weakness (especially neck and respiratory
muscles) or wasting (especially limbs) Electrophysiological study
Cranial nerve palsies: III–VII, IX–XII (most typical:
facial palsy) Stool culture for C. jejuni
Areﬂexia
SerologytoC.jejuni,Cytomegalovirus,Epstein-
Barr Virus, Herpes Simplex Virus, HIV, M.
pneumoniae
Sensory dysfunctions Pain Magnetic resonance imaging
Numbness, paraesthesiae Electrocardiogram
Ataxia Blood pressure monitoring
Decrease or loss in proprioception, vibration, touch,
and pain distally Autonomic function tests
Autonomic dysfunctions Sinus tachycardia and bradycardia Antiganglioside antibodies
Other cardiac arrhythmias Biochemical screening: urea, electrolytes, liver
enzymes
Hypertension and postural hypotension Full blood count
Wide ﬂuctuations of pulse and blood pressure Erythrocyte sedimentation rate or C-reactive
protein
Hypersalivation








three days before presentation at our OPD, he had been
showing progressive asthenia, with increasing weakness at
all limbs, dysarthria, and dysphagia. He was immediately
hospitalised.
At entry he was confused, with amimic face, bilateral
facial palsy (prevalent on the right), all limbs weakness (right
side more than left), generalized hyporeﬂexia or areﬂexia at
all limbs, anhysocoria (left>right), and heart rate 90bpm,
withbloodpressure(BP)ascendinginacoupleofhoursfrom
110/70 to 170/100. Skin rash was not anymore visible.
Among blood tests performed there was a mild increase
in liver enzymes (complete results in Table 2). Antibodies
for HIV-1 were detected, and conﬁrmation test was positive.
CD4+lymphocytecountwas710/mm3 (45%),andviralload
was 4,400 copies of HIV-RNA/mL.
One day after hospitalisation MRI scan of brain and
truncus showed no speciﬁc signs (Table 2). The neurologist
consultant then recommended lumbar puncture in the sus-
pect of GBS. Lumbar puncture was performed on the third
day. CSF examination showed 3cells/mm3 and increased
protein level (291mg/dL), a pattern compatible with GBS
[1]. Electroencephalogram was normal. BP was irregular,
but gradually under control with antihypertensive drugs.
Electrophysiological study was scheduled.
On the ﬁfth day, the patient presented a worsening
of limb weakness (both proximal and distal); anhysocoria
was not anymore visible. He was started on intravenous
immunoglobulins (IVIG) (400mg/kg/day). Three days later
he suddenly died because of cardiac arrest; prolonged
resuscitation procedures were ineﬀective.
3. Discussion
The mechanisms proposed for GBS in HIV-1-infected
patients include a direct action of HIV-1 on the nerves by
neurotropic strains, or autoimmune mechanisms, with the
formation of antibodies against myelin secondary to the
abnormal immunoregulation determined by HIV infection
[13]. The onset of GBS in this case coincided with the
acute retroviral syndrome of HIV, during the phase of ini-
tial immune reconstitution following serologic conversion,
as observed in other cases reported in the literature [6,
7]. Although GBS in HIV-infected subjects has generallyCase Reports in Infectious Diseases 3
Table 2: Results of diagnostic investigations during hospitalization.
Laboratory
investigations
Blood alanine-aminotransferase (AST) 80U/L (2×ULN)
aspartate-aminotransferase (ALT) 103U/L (>2.5ULN)
Total bilirubin 1.8mg/dL (normal<1.2)
lactic dehydrogenase (LDH) 603U/L (normal<460)
HIV-Ab (including RIBA) Positive
CD4+ cell count and % 710/mL; 45%
CD8+ cell count and % 595/mL; 37%
CD4+/CD8+ ratio 1.2
HIV viral load 4,400 copies of HIV-RNA/
mL
Hepatitis B virus markers HBs-Ab, total HBcAb, and
HBeAb: positive
haemochrome, C-reactive protein, blood sugar, uraemia, creatinine, γ-glutamil-
transpeptidase, alkaline phosphatase, creatine-phosphokinase, amylase, lipase,
triglycerids, ions, protidogram, immunoglobulins (total IgG, IgM, IgA), Hepatitis
C Virus-Ab, coagulation tests, complement fractions (C3 and C4), ANA, syphilis
tests (TPHA and RPR), and urine analysis
Negative or within normal
ranges
Cerebrospinal
ﬂuid Cells 3/mL (all mononuclear cells)
Proteins 291mg/dL
Protein analysis
Barrier damage with propor-
tional increase in IgG and
albumin
HIV viral load Not detectable
Glucose, oligoclonal IgG bands, culture for bacteria and fungi, and syphilis tests
(TPHA and RPR)
Negative or within normal
ranges
a favourable outcome, rapid worsening of clinical conditions
such as respiratory failure has been reported [7].
Both plasmapheresis and IVIG have been used to treat
GBS in HIV-infected individuals [14–16]. The reported
results have ranged from ineﬀe c t i v ea n dm i l db e n e ﬁ tt o
good response [6, 14]. Nevertheless, IVIG currently remains
the preferred choice in treating GBS. IVIG is preferred to
plasmapheresis because of greater convenience, with overall
comparable cost and equal eﬃcacy [1, 17].
Twenty-ﬁve percent of all GBS patients require ventilator
support of some type, and many of them require access
to ICU [1]. Nevertheless, outcomes after ICU care were
reported to be similar in HIV-positive and HIV-negative
patients with GBS [18].
Unfortunately, in our case the rapid fatal evolution
did not allow for ICU support. Cases with autonomic
disturbances have been reported with similar evolution.
Many deaths due to GBS are in fact attributed to autonomic
disturbances; cardiac arrest being the most common cause,
responsible for 20–30% of deaths [2]. Approximately 25% of
deaths occur within the ﬁrst week of onset of GBS.
Some conclusions can be drawn from this case. First,
it is necessary to consider the possibility of GBS when
patients are diagnosed with a symptomatic acute HIV
syndrome. Patients could be advised to promptly report any
neurological symptom or sign suggestive of GBS. This would
allow for early diagnosis and proper timely management,
includingtreatmentandsupport.Second,theoppositeisalso
true:incasesofGBS,HIVinfectionshouldbeconsideredand
searched. Last, but not less important, HIV-infected patients
with GBS should be accurately monitored, because serious
complications and fatal outcome of the disease are possible
as in the HIV-uninfected.
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